anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain an antifungal agent preparation having improved adhesivity to the surface of skin, good drug absorption, showing neither greasiness nor removal by rubbing, containing an antifungal agent, a polymer having film- forming ability and an organic solvent capable of dissolving the polymer. CONSTITUTION:An antifungal agent preparation containing an antifungal agent, a polymer (having preferably <=16C glass transition point, such as polyvinyl acetate, ethylene-vinyl acetate copolymer, etc.) which is soluble in an organic acid and has film-forming ability and the organic solvent capable of dissolving the polymer. Preferably the amount of the antifungal agent is 0.1-5pts.wt. based on 100pts.wt. polymer and the amount of the solvent is 100-3,000pts.wt. The preparation is further blended with 0.5-20pts.wt. absorption promoter (e.g. salicylic acid or urea). A polymer coating film formed on the skin surface is slightly water-soluble, will not swell with moisture, is not deformed, not dissolved in absorbed water, protects the skin for a long time and makes the contained drug act sufficiently.
INTRODUCTION AND OBJECTIVES: Cardiogenic shock (CS) has long been considered a contraindication for the use of non-invasive ventilation (NIV). The main objective of this study was to analyze the effectiveness, measured as NIV success, in patients with respiratory failure due to CS. As secondary objective, we studied risk factors for NIV failure and compared the outcome of patients treated with NIV versus invasive mechanical ventilation (IMV).
METHODS: Retrospective study on a prospective database, over a period of 25 years, of all consecutively patients admitted to an intensive care unit, with a diagnosis of CS and treated with NIV. A comparison was made between patients on NIV and patients on IMV using propensity score matching analysis.
RESULTS: Three hundred patients were included, mean age 73.8 years, mean SAPS II 49. The main cause of CS was acute myocardial infarction (AMI): 164 (54.7%). NIV failure occurred in 153 (51%) cases. Independent factors for NIV failure included D/E stages of CS, AMI, NIV related complications, and being transferred from the ward. In the propensity analysis, hospital mortality (OR 1.69, 95% CI 1.09-2.63) and 1 year mortality (OR 1.61, 95% CI 1.04-2.51) was higher in IMV. Mortality was lower with NIV (vs. EIT-IMV) in C stage (10.1% vs. 32.9%; p<0.001) but did not differ in D stage or E stage.
CONCLUSIONS: NIV seems to be relatively effective and safe in the treatment of early-stage CS.
Arm I is given XDd regimen (ATG-010(Selinexor) 80mg/d QW, Pegylated liposomal doxorubicin 25mg/m2, d1and Dexamethasone 40mg/d QW) in approximately 25 subjects. 4 weeks per cycle and include a total of 12 cycles.
The invention discloses Lachnum sp., an extracellular polysaccharide thereof and application of the extracellular polysaccharide in preparing lipid-lowering liver-favoring medicaments. The invention is characterized in that a Lachnum sp. strain with the collection number of CCTCC (China Center for Type Culture Collection) No: M 2011196 is activated and inoculated to a fermentation culture medium, thus preparing the Lachnum sp. extracellular polysaccharide. When the administration dosage is 150-300 mg/(kg bw), the prepared Lachnum sp. extracellular polysaccharide can significantly lower the levels of serum lipid and liver lipid and atherosis index of high-lipid mice, and increase the level of serum high-density lipoprotein cholesterol and the excretion amount of feces lipid. When the administration dosage is 75-300 mg/(kg bw), the prepared Lachnum sp. extracellular polysaccharide can significantly lower the activity of serum aminotransferase and malondialdehyde content in liver tissues of high-lipid mice, and increase the activity of sudismase in the liver tissues. The prepared Lachnum sp. extracellular polysaccharide has obvious effects of lowering blood lipid, lowering liver lipid, and treating hepatic injury and dysfunction caused by high lipid, has no toxic or side effects, and can be prepared into tablets or capsules for clinical application.
Ethically difficult situations are a part of the everyday clinical practice for health care professionals and concerns difficult judgements, prioritization and crucial decisions. Being unable or prevented to act according to one's moral conviction for what is good and right care may increase the risk for health care professionals to experience moral distress. Moral distress has been described as a condition with frustration, guilt, anger and as one reason for health care professionals to leave the profession. Ethics communication in groups has been showed to work as support for health care professionals in ethically difficult situations and further work as a tool to improve the ethical climate and prevent moral distress. Our research group has developed the "one to five-step method" for interprofessional ethical communication in groups. The method is a stepwise support for facilitating ethics communication in clinical practice when the situations occurs. The overall aim of this project: is to implement and evaluate a method for organized interprofessional communication about ethical issues in healthcare.

Significance: The study can generate knowledge about ethics communication in groups in line with the " one to five step method", reduce moral distress, create improved ethical climate for healthcare professionals and in turn open up prerequisites for good care.
Patients will be grouped into three groups; each group composed of 15 patients suffering from CMNP. The personal history of each patient who participated in the study will be collected, the patient will receive an oral explanation of the procedures and signed a consent form . The weight and height of each patient will be obtained using the standard weight scale. The pain intensity level will be assessed via a visual analogue scale (VAS). The disability level will be assessed via neck disability index (NDI). The forward head posture will be assessed via photographic method of Craniovertebral angle (CVA) and the angle will be calculated by using kinovea software. The range of motion will be assessed via universal goniometer (UG). The endurance of the neck muscles will be assessed via pressure biofeedback unit (PBU). Assessment will be done before treatment and after 12 treatment sessions.
NEW MATERIAL:A compound expressed by formula I [A is formula V (R is 1-12C alkyl, cycloalkyl or phenyl which may have mercapto as a substituent group) or formula VI]. EXAMPLE:A-Homo-3a-aza-14-hydroxy-3-methylthio-5beta, 14beta-carda-3( 3a )-20( 22 )-dienolide. USE:A cardiotonic agent, having action of increasing the myocardial contractive force (positive inotropic action), and useful for treating cardiopathy, e.g. congestive failure, and very weak side effects, e.g. abnormal electrocardiograph, as compared with those of the conventional digitalis cardiotonic agent. PREPARATION:A compound expressed by formula IIa is reacted with a sulfonyl halide expressed by formula III (X is halogen; R<1> is aryl, etc.; R<2> is alkyl) in the presence of a dehydrohalogenating agent in an inert organic solvent to give a reaction product, which is then subjected to the Beckmann rearrangement reaction with an aluminum sulfide reagent expressed by formula IV to afford the aimed compound expressed by formula I a.
Women randomized to the adherence arm will attend 3 prenatal sessions and 2 postpartum sessions with a peer facilitator. Each session will be delivered on an individual basis and consist of structured educational content followed by unstructured conversation, allowing the participant to ask questions and actively engage in formulating her plan to be retained in HIV care. The goal of the prenatal sessions is to introduce the intervention, foster bonding, and address outcome expectancies and self-efficacy regarding retention in HIV care postpartum. The postpartum sessions build on outcome expectancies and self-efficacy to develop skills for Antiretroviral therapy (ART) adherence and engagement in HIV care.
The invention relates to aerosol compositions for body care, which contain - at least one propellant and - at least one composition A, which contains a) at least one ester which is formed from at least one linear or branched, saturated or unsaturated alcohol having 4 to 30 carbon atoms and at least one linear or branched, saturated or unsaturated carboxylic acid having 8 to 30 carbon atoms, and b) at least one ester which is formed from at least one C 2 -C 7  mono-, di-, or tricarboxylic acid, which can optionally contain one or more hydroxyl groups, and at least one linear or branched, saturated or unsaturated alcohol having 1 to 30 carbon atoms. Composition A contains at most 2 wt% of free water relative to the total weight of composition A. The weight ratio of ester a) : ester b) in composition A is 4.5 : 1 to 1.5 : 1. The invention further relates to a deodorising aerosol composition for body care, which contains, in relation to the total weight of the deodorising aerosol composition, - 10 to 90 wt% of at least one propellant, selected from propane, n-butane, isobutane, n-pentane, isopentane, dimethyl ether, carbon dioxide, dinitrogen oxide, fluorocarbons, and/or chlorofluorocarbons, and - 1 to 40 wt% of at least one composition A, which contains a) at least one ester which is formed from at least one linear or branched, saturated or unsaturated alcohol having 4 to 30 carbon atoms and at least one linear or branched, saturated or unsaturated carboxylic acid having 8 to 30 carbon atoms, b) at least one ester which is formed from at least one C 2 -C 7  mono-, di-, or tricarboxylic acid, which can optionally contain one or more hydroxyl groups, and at least one linear or branched, saturated or unsaturated alcohol having 1 to 30 carbon atoms, and c) at least one antiperspirant active ingredient. Composition A contains at most 2 wt% of free water, relative to the total weight of composition A. The weight ratio of ester a) : ester b) in composition A is 4.5 :1 to 1.5 : 1. The compositions according to the invention are characterised in that the spray jet of said compositions has better focusing.
A new approach for targeting chemotherapeutics to focal bacterial infections is provided. Such focal infections are characterized by high densities of different bacteria and thus high concentrations of their extracellular signal molecules sensing the cell density. In gram-negative bacteria, one of such signal molecules is acylhomoserine lactone (acyl-HSL, member of the autoinducer family AI-1), wherein species-specificity is achieved by acyl-residues, and HSLs are common for all gram-negative bacteria. In gram-positive bacteria, oligopeptides secreted by the bacteria communicate the cell density. In addition, there are cell density signal molecules (members of the autoinducer family AI-2) which communicate between gram-positive and gram-negative bacteria. The general scheme of the present invention is molecular modules that comprise both a targeting component and a chemotherapeutical component which serves for photodynamic antimicrobial chemotherapy (PACT). One preferred embodiment of the present invention is to target photosensitizers to the extracellular signal molecules instead of on the bacteria themselves. Targeting of the photosensitizers is mediated via molecules with efficient binding to the HSL-moiety of the acyl-HSL, so that a broad spectrum of gram-negative bacteria can be knocked out. Photosensitizers used in the present invention can be packed into special liposomes with lipid chelators or multiple coupled to dendrimers, so that they are especially effective for PACT. In addition, selected molecules with high affinity to a common moiety of such signal molecules, like HSL, may be used as molecular probes for the search of yet undiscovered cell density dependent signals.
Patients received one treatment at baseline with verteporfin placebo (with sham photodynamic therapy) in the study eye and thereafter based on re-treatment criteria at intervals of at least 90 days. Within 1-24 hours, patients also received Ranibizumab intravitreal injection on Day 1 and at Month 1 and 2 and thereafter according to the re-treatment criteria at intervals of at least 30 days through Day 150. From month 3 onward, re-treatments were determined based on study-specific re-treatment criteria that included evaluation of polyp progression on indocyanine green angiography (ICGA), and assessment of fluorescein angiograms and visual acuity.
Risk Summary 

There are no available data on the effects of budesonide and formoterol fumarate dihydrate, budesonide or formoterol fumarate on the breastfed child or on milk production. Budesonide, like other inhaled corticosteroids, is present in human milk [see Data]. There are no available data on the presence of formoterol fumarate in human milk. Formoterol fumarate is present in rat milk [see Data]. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for budesonide and formoterol fumarate dihydrate and any potential adverse effects on the breastfed infant from budesonide and formoterol fumarate dihydrate or from the underlying maternal condition.

Data

Human data with budesonide delivered via dry powder inhaler indicates that the total daily oral dose of budesonide available in breast milk to the infant is approximately 0.3% to 1% of the dose inhaled by the mother [see Clinical Pharmacology (12.3)]. For budesonide and formoterol fumarate dihydrate, the dose of budesonide available to the infant in breast milk, as a percentage of the maternal dose, would be expected to be similar.

In the fertility and reproduction study in rats, plasma levels of formoterol were measured in pups on post-natal day 15 [see Use in Specific Populations (8.1)]. It was estimated that the maximum plasma concentration that the pups received from the maternal animal, at the highest dose of 15 mg/kg, after nursing was 4.4% (0.24 nmol/L for a litter vs. 5.5 nmol/L for the mother).
A method of preparation of a stable oil containing long-chain polyunsaturated fatty acids in the form of triacylglycerols by dry pressing one or more biomass deriving from the culture of a microorganism to obtain a first pressed oil and a cake and treating the oil with an absorbent and deodorizing in moderate conditions.  The triacylglycerols are especially arachidonic acid (ARA), dihomogammalinoleic acid (DHGLA), docosahexenoic acid (DHA) and eicosapentenoic acid (EPA). The biomass is especially from the culture of a fungus or microalga. The pressed cake is contact with a support oil forming part of an alimentary, nutritional, pharmaceutical or cosmetic composition to transfer remaining long-chain fatty acids. The oil is separated, filtered and mixed with the first oil and refined under moderate conditions. Physical refining with the aid of a process agent is carried out during contact with the support oil or after obtaining the pressed oil. The pressed cake may be ground in the presence of the support oil under gentle conditions at a moderate temperature under an inert gas atmosphere.
Subjects will first spend 10 minutes in a dry sauna at 85 degrees celtius. Immediately after , subjects will be immersed in a cold water bath (ICool , Australia) at a temperature of 5 degrees celtius for approximately one minute. Blood pressure , ecg , gaz exchange and thoracic impedance will be measured during sauna and cold water bath.
Aminopeptidase N (APN/CD13) is a widely expressed transmembrane ectoenzyme that is crucial for maintaining normal physiological activities. It exhibits abnormal activity closely associated with hepatic fibrosis and nonalcoholic fatty liver disease (NAFLD). Therefore, there is a high demand for noninvasive detection of aminopeptidase N (APN) in the diagnosis and research of related diseases. Here, we developed a small molecule fluorescent probe, Hcy-APN, which is a fluorescent probe with high sensitivity and selectivity for the detection of APN. Furthermore, we synthesized the fluorescent nanoprobe Hcy-APN@MSN by self-assembling Hcy-APN and mesoporous silica nanoparticles in solution using a combination of molecular probe design and nanofunctionalization strategies. The detection limit of this probe was 1.5 ng/mL. Hcy-APN@MSN exhibits more stable spectral characteristics compared to Hcy-APN and is suitable for detecting APN activity in live cells and mice. Hcy-APN@MSN was utilized for in vivo and intracellular imaging of NAFLD and hepatic fibrosis at different stages, as well as for a systematic assessment of APN levels in the liver. The results confirm an elevation in the expression levels of APN in NAFLD and hepatic fibrosis models. Furthermore, we investigated the inhibitory effect of the APN inhibitor bestatin in nonalcoholic fatty liver and hepatic fibrosis disease models, confirming its regulatory effect on APN levels in cells and in vivo in both disease models. Therefore, this study may offer diagnostic possibilities for detecting NAFLD and hepatic fibrosis.
The preschool years are a critical time to begin obesity prevention efforts as they represent a time when young children establish healthy eating habits and physical activity patterns. These habits can place children at risk for obesity and are shaped by many characteristics, including individual characteristics as well as school, family and societal environmental characteristics. Predictive behaviors, or behavioral antecedents, within these environments can influence child behaviors. While many predictive behaviors have been shown to influence dietary intake, physical activity, and weight status, two potential behavioral antecedents - food preference and motor performance - need further exploration. Understanding the context in which child behavioral patterns are developed is critical to developing a model to address childhood obesity.

The Colorado LEAP project is a longitudinal cohort study utilizing a controlled quasi-experimental design in 5 rural Colorado communities. Two communities serve as intervention communities with the other 3 as matched controls. Intervention sites receive The Food Friends® nutrition and physical activity programs in preschool and 'booster' programming in kindergarten and 1st grade. Assessments are administered 4 times - twice in preschool (Fall and Spring) and once in both kindergarten and 1st grade (Spring). Observational measures with children are conducted at the school; parent/home measures are sent home and returned to school via the child; and school personnel complete school environment and policy assessments.
Non-Japanese participants. TAK-828 0.1 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 15 mg, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
BACKGROUND: One of the common concerns of healthcare systems is the potential for re-admission of COVID-19 patients. In addition to adding costs to the healthcare system, re-admissions also endanger patient safety. Recognizing the factors that influence re-admission, can help provide appropriate and optimal health care. The aim of this study was to assess comorbidities that affect re-admission and survival in COVID-19 patients using a joint frailty model.
METHODS: This historical cohort study was done using data of patients with COVID-19 who were re-hospitalized more than twice in a referral hospital in North of Iran. We used the joint frailty model to investigate prognostic factors of survival and recurrence, simultaneously using R version 3.5.1 (library "frailtypack"). P-values less than 0.05 were considered as statistically significant.
RESULTS: A total of 112 patients with mean (SD) age of 63.76 (14.58) years old were recruited into the study. Forty-eight (42.9%) patients died in which 53.83% of them were re-admitted for a second time. Using adjusted joint model, the hazard of re-admission increased with cancer (Hazard ratio (HR) = 1.92) and hyperlipidemia (HR = 1.22). Furthermore, the hazard of death increased with hyperlipidemia (HR = 4.05) followed by age (HR = 1.76) and cancer (HR = 1.64). It Also decreased with lung disease (HR = 0.11), hypothyroidism (HR = 0.32), and hypertension (HR = 0.97).
CONCLUSION: Considering the correlation between re-admission and mortality in the joint frailty model, malignancy and hyperlipidemia increased the risk of both re-admission and mortality. Moreover, lung disease probably due to the use of corticosteroids, was a protective factor against both mortality and re-admission.
The Intervention Arm in the Promise Women Project evaluates a specific educational intervention program for Muslim women to promote cervical cancer prevention. It involves a one-time, 90-minute culturally and religiously tailored educational session with 20 participants. The session covers perceived risks of Human Papilloma Virus (HPV) infection, cervical cancer, and benefits of early screening and vaccination. Pre- and post-intervention surveys measure changes in participants' knowledge. This experimental arm assesses the intervention's effects on knowledge and acceptance of cervical cancer prevention.
Reading requires the transformation of a complex array of visual features into sounds and meaning. For deaf signers who experience changes in visual attention and have little or no access to the sounds of the language they read, understanding the visual constraints underlying reading is crucial. This study aims to explore a fundamental aspect of visual perception intertwined with reading: the crowding effect. This effect manifests as the struggle to distinguish a target letter when surrounded by flanker letters. Through a two-alternative forced choice task, we assessed the recognition of letters and symbols presented in isolation or flanked by two or four characters, positioned either to the left or right of fixation. Our findings reveal that while deaf individuals exhibit higher accuracy in processing letters compared to symbols, their performance falls short of that of their hearing counterparts. Interestingly, despite their proficiency with letters, deaf individuals didn't demonstrate quicker letter identification, particularly in the most challenging scenario where letters were flanked by four characters. These outcomes imply the development of a specialized letter processing system among deaf individuals, albeit one that may subtly diverge from that of their hearing counterparts.